Skip to main content

COSOSA

Anthracycline Cardiotoxicity in Adult Cancer Patients

Published:  17 September 2024

JACC: CARDIOONCOLOGY State-of-the-Art Review

Since their introduction in the 1960s, anthracyclines have been a significant breakthrough in oncology, introducing dramatic changes in the treatment of solid and hematologic malignancies. Although new-generation targeted drugs and cellular therapies are revolutionizing contemporary oncology, anthracyclines remain the cornerstone of treatment for lymphomas, acute leukemias, and soft tissue sarcomas.